NFKB1 and Miyoshi myopathy: Bortezomib inhibits inducible NF-κB activity in MM cells, but unexpectedly enhances constitutive NF-κB activity via activation of the canonical pathway, which elevate sheparanase protein expression and tumor necrosis factor alpha (TNF-α) production (28).